secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001104659-23-057516
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure Q1 net loss $77.2M ($1.63/shr); cash $315.3M; on track for AMT-130 data Q2
--------------------------------------------------------------------------------

- Revenue $5.3M (up from $1.8M YoY) on $4.9M contract manufacturing for HEMGENIX.
- Eligible for $100M milestone from CSL on first US commercial sale of HEMGENIX; $75M European milestone by July 2, 2023.
- Huntington's disease AMT-130: 1-2 year follow-up data from US Phase I/II expected Q2 2023; higher-dose enrollment in EU trial to complete mid-2023.
- Pipeline advancing: AMT-162 (SOD1-ALS) Phase I/II start H2 2023; AMT-260 (epilepsy) and AMT-191 (Fabry) IND filings in 2023.
- Cash $315.3M expected to fund operations into 2025 ($100M milestone assumed) or H1 2025 if $75M European milestone achieved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/0001104659-23-057516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465923057516/tm2315123d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer